Gene expression profiles can predict panitumumab monotherapy responsiveness in human tumor xenograft models

Neoplasia (United States)

Volumn 15, Issue 2, 2013, Pages 125-132

  Boedigheimer, Michael J ^a   Freeman, Daniel J ^a   Kiaei, Panteha ^a   Damore, Michael A ^a   Radinsky, Robert ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PANITUMUMAB; PROTEIN P73;

ALGORITHM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENE CONTROL; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; MONOTHERAPY; MOUSE; NEOPLASM; NONHUMAN; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; TUMOR XENOGRAFT;

EID: 84873492495     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.121038     Document Type: Article

References (46)

1. Yarden Y and Sliwkowski MX (2001). Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2, 127-137.
2. Cohenuram M and Saif MW (2007). Panitumumab the first fully human monoclonal antibody: from the bench to the clinic. Anticancer Drugs 18, 7-15.
3. Herbst RS and Shin DM (2002). Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 94, 1593-1611.
4. Ritter CA and Arteaga CL (2003). The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors. Semin Oncol 30, 3-11.
5. Gullick WJ, Hughes CM, Mellon K, Neal DE, and Lemoine NR (1991). Immuno-histochemical detection of the epidermal growth factor receptor in paraffin-embedded human tissues. J Pathol 164, 285-289.
6. Nicholson RI, Gee JM, and Harper ME (2001). EGFR and cancer prognosis. Eur J Cancer 37, S9-S15.
7. Foon KA, Yang XD, Weiner LM, Belldegrun AS, Figlin RA, Crawford J, Rowinsky EK, Dutcher JP, Vogelzang NJ, Gollub J, et al. (2004). Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys 58, 984-990.
8. Yang XD, Jia XC, Corvalan JR, Wang P, and Davis CG (2001). Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 38, 17-23.
9. Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG, and Jakobovits A (1999). Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res 59, 1236-1243.
10. Jakobovits A, Amado RG, Yang X, Roskos L, and Schwab G (2007). From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice. Nat Biotechnol 25, 1134-1143.
11. Vectibix® (Panitumumab). Full Prescribing Information (2011). Amgen Inc, Thousand Oaks, CA.
12. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, et al. (2004). Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351, 337-345.
13. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, and Mayer RJ (2004). Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22, 1201-1208.
14. Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon JL, Van Laethem JL, Maurel J, Richardson G, et al. (2007). Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25, 1658-1664.
15. Van Cutsem E, Siena S, Humblet Y, Canon JL, Maurel J, Bajetta E, Neyns B, Kotasek D, Santoro A, Scheithauer W, et al. (2008). An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Ann Oncol 19, 92-98.
16. Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, et al. (2007). Cetuximab for the treatment of colorectal cancer. N Engl J Med 357, 2040-2048.
17. Douillard J, Cassidy J, Jassem J, Rivera F, Kocáková I, Rogowski W, Canon JR, Yanez EP, Xu F, and Gansert JL (2010). Randomized, open-label, phase III study of panitumumab (pmab) with FOLFOX4 versus FOLFOX4 alone as first-line treatment (tx) for metastatic colorectal cancer (mCRC): efficacy by skin toxicity (ST) [abstract]. J Clin Oncol 28, 3528.
18. Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pinter T, Lim R, Bodoky G, et al. (2009). Cetuximab and chemo-therapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360, 1408-1417.
19. Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, Lorimer I, Zhang T, Liu N, Daneshmand M, et al. (2005). Erlotinib in lung cancer- molecular and clinical predictors of outcome. N Engl J Med 353, 133-144.
20. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, et al. (2008). Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26, 1626-1634.
21. Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, Cote JF, Tomasic G, Penna C, Ducreux M, et al. (2006). KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66, 3992-3995.
22. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, Zanon C, Moroni M, Veronese S, Siena S, and Bardelli A (2007). Oncogenic activation of the RAS/ RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 67, 2643-2648.
23. Frattini M, Saletti P, Romagnani E, Martin V, Molinari F, Ghisletta M, Camponovo A, Etienne LL, Cavalli F, and Mazzucchelli L (2007). PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 97, 1139-1145.
24. Freeman DJ, Juan T, Reiner M, Hecht JR, Meropol NJ, Berlin J, Mitchell E, Sarosi I, Radinsky R, and Amado RG (2008). Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone. Clin Colorectal Cancer 7, 184-190.
25. Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, Wu S, Wong TW, Huang X, Takimoto CH, Godwin AK, et al. (2007). Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 25, 3230-3237.
26. Virtanen C and Woodgett J (2008). Clinical uses of microarrays in cancer research. Methods Mol Med 141, 87-113.
27. Chung CH, Seeley EH, Roder H, Grigorieva J, Tsypin M, Roder J, Burtness BA, Argiris A, Forastiere AA, Gilbert J, et al. (2010). Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients. Cancer Epidemiol Biomarkers Prev 19, 358-365.
28. de Reynies A, Boige V, Milano G, Faivre J, and Laurent-Puig P (2008). KRAS mutation signature in colorectal tumors significantly overlaps with the cetuximab response signature. J Clin Oncol 26, 2228-2230; author reply 2230-2221.
29. Jacobs B, De Roock W, Piessevaux H, Van Oirbeek R, Biesmans B, De Schutter J, Fieuws S, Vandesompele J, Peeters M, Van Laethem JL, et al. (2009). Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol 27, 5068-5074.
30. Liu F and Wu B (2007). Multi-group cancer outlier differential gene expression detection. Comput Biol Chem 31, 65-71.
31. GeneChip® Expression Analysis Technical Manual P/N 701024 Rev. 1 (2009). Affymetrix Inc, Santa Clara, CA.
32. Bolstad BM, Irizarry RA, Astrand M, and Speed TP (2003). A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19, 185-193.
33. Goldberg DE (1989). Genetic Algorithms in Search, Optimization and Machine Learning. Addison-Wesley Longman Publishing, Boston, MA.
34. Aliferis CF, Tsamardinos I, Massion P, Statnikov A, and Hardin D (2003). Why classification models using array gene expression data perform so well: a preliminary investigation of explanatory factors. In International Conference on Mathematics and Engineering Techniques in Medicine and Biological Sciences, June 23-26, 2003, Las Vegas, NV.
35. Hastie T, Tibshirani R, and Friedman J (2001). The Elements of Statistical Learning: Data Mining, Inference, and Prediction. Springer, New York, NY.
36. Ambroise C and McLachlan GJ (2002). Selection bias in gene extraction on the basis of microarray gene-expression data. Proc Natl Acad Sci USA 99, 6562-6566.
37. Kutner MH (2005). Applied Linear Statistical Models. McGraw-Hill Irwin, Boston, MA.
38. Efron B and Tibshirani R (2002). Empirical bayes methods and false discovery rates for microarrays. Genet Epidemiol 23, 70-86.
39. Miller AJ (1990). Subset Selection in Regression. Chapman and Hall, London, UK.
40. Rocha-Lima CM, Soares HP, Raez LE, and Singal R (2007). EGFR targeting of solid tumors. Cancer Control 14, 295-304.
41. Siena S, Tabernero J, Cunningham D, Koralewski P, Ruff P, Rother M, Johnson CW, Zhang A, Gansert JL, and Douillard J (2010). Randomized phase III study of panitumumab (pmab) with FOLFOX4 compared to FOLFOX4 alone as first-line treatment (tx) for metastatic colorectal cancer (mCRC): PRIME trial analysis by epidermal growth factor receptor (EGFR) tumor staining [abstract]. J Clin Oncol 28, 3566.
42. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al. (2000). Molecular portraits of human breast tumours. Nature 406, 747-752.
43. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, Coller H, Loh ML, Downing JR, Caligiuri MA, et al. (1999). Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286, 531-537.
44. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, et al. (2000). Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403, 503-511.
45. Nguyen DV and Rocke DM (2002). Partial least squares proportional hazard regression for application to DNA microarray survival data. Bioinformatics 18, 1625-1632.
46. Vikhanskaya F, Bani MR, Borsotti P, Ghilardi C, Ceruti R, Ghisleni G, Marabese M, Giavazzi R, Broggini M, and Taraboletti G (2001). A p73 Overexpression increases VEGF and reduces thrombospondin-1 production: implications for tumor angiogenesis. Oncogene 20, 7293-7300.